Login to Your Account



More Pricing Power Won't Be 'NICE' to Biopharma: ABPI

By Nuala Moran
Staff Writer

Wednesday, March 27, 2013
The shape of the UK's new drug pricing regime became clearer when the government confirmed it is handing responsibility for assessing the value of medicines to the National Centre for Health and Clinical Excellence (NICE), a body that has repeatedly clashed with the industry over its decisions on whether drugs should be funded by the National Health Service.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription